Conduit Enterprise Value Over E B I T D A from 2010 to 2025

CDTTW Stock   0.01  0.0001  0.89%   
Conduit Pharmaceuticals Enterprise Value Over EBITDA yearly trend continues to be fairly stable with very little volatility. Enterprise Value Over EBITDA is likely to outpace its year average in 2025. During the period from 2010 to 2025, Conduit Pharmaceuticals Enterprise Value Over EBITDA regression line of quarterly data had mean square error of 353.3 B and geometric mean of  213,075. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
4.27459596
Current Value
4.49
Quarterly Volatility
871.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Conduit Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Conduit Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 143.6 K, Selling General Administrative of 4.1 M or Total Revenue of 2.6 B, as well as many indicators such as Price To Sales Ratio of 0.088, Dividend Yield of 0.0235 or PTB Ratio of 0.23. Conduit financial statements analysis is a perfect complement when working with Conduit Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Conduit Pharmaceuticals Correlation against competitors.
For more information on how to buy Conduit Stock please use our How to Invest in Conduit Pharmaceuticals guide.

Latest Conduit Pharmaceuticals' Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Conduit Pharmaceuticals over the last few years. It is Conduit Pharmaceuticals' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Conduit Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
100%
       Timeline  

Conduit Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean(1,474,131)
Geometric Mean213,075
Coefficient Of Variation(59.09)
Mean Deviation730,417
Median(1,961,075)
Standard Deviation871,131
Sample Variance758.9B
Range2M
R-Value0.75
Mean Square Error353.3B
R-Squared0.57
Significance0.0008
Slope137,587
Total Sum of Squares11.4T

Conduit Enterprise Value Over E B I T D A History

2025 4.49
2024 4.27
2023-47 K
2022 -6183.08

About Conduit Pharmaceuticals Financial Statements

Conduit Pharmaceuticals investors use historical fundamental indicators, such as Conduit Pharmaceuticals' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Conduit Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 4.27  4.49 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Conduit Stock Analysis

When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…